Personalized antisense oligonucleotide (CHCHD10 ALS)

antisense oligonucleotide targeting CHCHD10 · n-Lorem Foundation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Personalized antisense oligonucleotide (CHCHD10 ALS), covering 2025-07-25 to 2025-07-25. Get the full timeline:

Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS [Phase 1, Phase 2]

See pricing